Assessment of health economics in Alzheimer's disease (AHEAD): Treatment with galantamine in the UK

International Journal of Geriatric Psychiatry

Volumn 18, Issue 8, 2003, Pages 740-747

  Ward, A ^a   Caro, J Jaime ^a   Getsios, D ^b   Ishak, K ^b   O'Brien, J ^a   Bullock, R ^c  

^a CARO RESEARCH INSTITUTE   (United States)

^b Caro Research Institute   (Canada)

^c Kingshill Research Centre   (United Kingdom)

Author keywords

Alzheimer's disease; Cost effectiveness; Galantamine; UK

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; PREDICTION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GALANTAMINE; GREAT BRITAIN; HUMANS; MALE; MODELS, ECONOMETRIC; NOOTROPIC AGENTS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY;

EID: 0042011518     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.919     Document Type: Article

References (44)

1. Bosanquet N, May J, Johnson N. 1998. Alzheimer's Disease in the United Kingdom. Health Policy Review Paper no. 12. Health Policy Unit, Imperial College School of Medicine: London.
2. Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A. 2001. Assessment of health economics in Alzheimer's disease (AHEAD) based on the need for full time care. Neurology 57: 964-971.
3. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A, for the AHEAD Study Group. 2002a. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dementia and Geriatric Cognitive Disorders 14: 84-89.
4. Caro J, Ward A, Ishak K, Migliaccio-Walle K, Getsios D, Papadopoulos G, Torfs K. 2002b. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? BMC Neurology 12(2): 6.
5. Community Care Statistics. 2000. Residential personal social services for adults England. Department of Health. www.statistics.gov.uk/public/sb0028.htm.
6. Consumer price indices. January 2001. www.statistics.gov.uk/pdfdir/cpi0201.pdf.
7. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carrusi DA, Gornbein J. 1994. The Neuropsychiatric Inventory. Comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
8. Fenn P, Grey A. 1999. Estimating long-term cost savings from treatment of Alzheimer's disease: A modelling approach. Pharmacoeconomic 16(2): 166-174.
9. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-198.
10. Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. 2002. Asssessment of Health Economics in Alzheimer's Disease (AHEAD). Treatment with galantamine in Sweden. Pharmacoeconomics 20(9): 629-637.
11. Getsios D, Caro JJ, Caro G, Ishak K, for the AHEAD Study Group. 2001. Assessment of Health Economics in Alzheimer's Disease (AHEAD). Galantamine treatment in Canada. Neurology 57: 972-978.
12. Holmes J, Pugner K, Phillips R, Dempsey G, Cayton H. 1996. Managing Alzheimer's disease: The cost of care per patient. British Journal of Health Care Management 4(7): 332-337.
13. Isaacs B, Neville Y. 1976. The needs of old people: The interval as a method of measurement. Br J Prev and Soc Med 30: 79-85.
14. Kavanagh S, Knapp M. 1999. Cognitive disability and direct care costs for elderly people. Br J Psychiatry 174: 539-546.
15. Costs and cognitive disability: Modelling the underlying associations. 2002. Costs and cognitive disability: Modelling the underlying associations. Br J Psychiatry 180: 120-125.
16. Kavanagh S, Schneider J, Knapp M, Beecham J, Netten A. 1995. Elderly people with dementia: Costs, effectiveness, and balance of care. In Economic Evaluation of Mental Health Care, Knapp M (ed). Ashgate Publishing: Hants (England); 125-156.
17. Laing and Buisson. 2001. Care of Elderly People: Market Survey 2001, 14th edn. Laing and Buisson: London.
18. Mace S, Taylor D. 2002. Adherence to NICE guidelines for the use of anticholinesterases for Alzheimer's disease. The Pharmaceutical Journal 269: 680-681.
19. Martin J, Meltzer H, Elliot D. 1988. The Prevalence of Disability Among Adults: OPCS Surveys of Disability in Great Britain Report 1. HMSO: London.
20. McNamee P, Gregson BA, Buck D, Bamford CH, Bond J, Wright K. 1999. Costs of formal care for frail older people in England: The resource implications study of the MRC cognitive function and ageing study. Social Science and Medicine 48: 331-341.
21. Miller SC, Prohaska TR, Furner SE, Freels S, Brody JA, Levy PS. 1998. Time to nursing home admission for persons with Alzheimer's disease: The effect of health care system characteristics. J of Gerontol B Psychol Sci Soc Sci 53B(Suppl. 6): 341-353.
22. National Institute for Clinical Excellence. 2001. Guidance for Manufacturers and Sponsors. National Institute for Clinical Excellence: London.
23. National Institute of Clinical Excellence. 2001. Guidance on the Use of Donepezil (Aricept), Rivastigmine (Exelon) and Galantamine (Reminyl) for the Treatment of Alzheimer's Disease. Technology Appraisal Guidance (No. 19).
24. Netten A, Darton R, Bebbington A, Brown P. 2001a. Residential or nursing home care? The appropriateness of placement decisions. Aging and Society 21: 3-23.
25. Netten A, Darton R, Bebbington A, Forder J, Brown P, Mummery K. 2001b. Residential and nursing home care of elderly people with cognitive impairment: Prevalence, mortality and costs. Ageing and Mental Health 5(1): 14-22.
26. Netten A, Dennett J, Knight J. 1998. Unit Costs of Health and Social Care. Personal Social Services Research Unit (PSSRU). University of Kent, Canterbury.
27. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC, 1999. Health utilities in Alzheimer's disease: A cross-sectional study of patients and caregivers. Med Care 37(1): 27-32.
28. Office for National Statistics. 2002. Table 1.4. Population Trends No. 109; 63-65.
29. Payne KA, Wilson CM, Caro JJ, O'Brien J. 1999. Resource use by dementia patients and caregivers: An international survey of medical and social services and process of long-term care. Annals of Long-term Care 7(7): 263-276.
30. Raskind MA, Peskind ER, Wessel T, Yuan W. 2000. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54(12): 2261-2268.
31. Ribbe MW, Ljunggren G, Steel K, Topinkova E, Hawes C, Ikegami N, Henrard JC, Jonnson PV. 1997. Nursing homes in 10 nations: A comparison between countries and settings. Age Ageing 26(Suppl. 2): 3-12.
32. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, Segura E. 1993. The economic burden of Alzheimer's disease care. Health Aff (Millwood) 12(2): 164-175.
33. Rosen WG, Mohs RC, Davis KL. 1984. New rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
34. Scottish Health Service Costs (Year Ended 31st March 2000). 2000. Information and Statistics Division. National Health Service in Scotland: Edinburgh.
35. Small G, McDonnell D, Brooks R, Papadopoulos G. 2002. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc 50: 321-327.
36. Small GW, Rabins PV, Barry PP, et al. 1997. Diagnosis and treatment of Alzheimer disease and related disorders. JAMA 278(16): 1363-1371.
37. Souetre E, Thwaites RM, Yeardley HL. 1999. Economic impact of Alzheimer's disease in the United Kingdom. Br J Psychiatry 174: 51-55.
38. Stern Y, Tan MX, Albert MS, et al. 1997. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 277: 806-812.
39. Stewart A, Phillips R, Dempsey G. 1998. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 13(7): 445-453.
40. Tait C, Fuller E. 2002. Health Survey for England 2000: Psychosocial Well-Being Among Older People. The Stationery Office: London.
41. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C and the Galantamine USA-10 Study Group. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54: 2269-2276.
42. Wilcock GK, Lilienfeld S, Gaens E on behalf of the Galantamine International-1 Study Group. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicenter randomised controlled trial. Br Med J 321: 1-7.
43. Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA. 2000. Hallucinations, delusions and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 69(2): 172-177.
44. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T. 2002. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 181: 36-42.